Identified RP2 as a prognostic biomarker for glioma, facilitating glioma pathogenesis mainly via regulating tumor immunity
Figure 11.RP2 and immunotherapy. (A) Correlation between RP2 and various cell checkpoints. (B) TMB was low when RP2 was highly expressed. (C) TIDE score was high when RP2 expression was high which led to a poor immunotherapy effect.